Innovative Therapeutics Acetylon specializes in developing next-generation, selective HDAC enzyme inhibitors targeting a broad range of indications including cancers, inflammatory, neurodegenerative, genetic, and infectious diseases, providing multiple avenues for pharmaceutical collaboration and drug development partnerships.

Strategic Acquisition Having been acquired by Celgene for $30 million, Acetylon is now positioned as a part of a larger biotech portfolio, potentially opening opportunities for integrated solutions, co-development, and expanded partnership initiatives with Celgene or similar pharma companies interested in epigenetic therapies.

Research & Technology Licensed technology from Harvard University and Dana Farber enhances Acetylon’s credibility and innovation edge, making it an attractive partner for organizations seeking cutting-edge research collaborations or licensing opportunities in biologics and targeted epigenetic treatments.

Funding & Growth With recent funding of approximately $100 million and a revenue range between $1 million and $10 million, Acetylon demonstrates substantial financial backing and growth potential, presenting an opportunity for investors or partners looking to enter the epigenetics space with a focus on innovative pharmaceuticals.

Market Focus & Trends Targeting multiple high-growth therapeutic areas such as oncology, autoimmune, and infectious diseases, Acetylon aligns with current market trends favoring precision medicine and epigenetic drug development, making it a strategic partner for organizations targeting these expanding segments.